The Company announced the council’s deliberation results on Tabneos and the planned response. A request to refrain from initiating new treatments and instructions to consider alternative treatments for currently treated patients were issued. The impact on business performance is under review and will be disclosed once determined. A drug consultation center has been set up and contact details provided.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-22","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4547-20261022-01.pdf","jir_short_summary":"The Company announced the council's deliberation results on Tabneos and the planned response. A request to refrain from initiating new treatments and instructions to consider alternative treatments for currently treated patients were issued. The impact on business performance is under review and will be disclosed once determined. A drug consultation center has been set up and contact details provided.","jir_summary":"### Key Points\nThis matter concerns the deliberation results at the Ministry of Health, Labour and Welfare's Pharmaceutical Affairs and Food Sanitation Council for Tabneos (generic name: abacopan) and the announced future usage policy. The council judged that there are doubts about the reliability of the submitted materials and concluded that it cannot be determined that the benefits outweigh the risks. As measures, it requested refraining from initiating new treatments, and for patients currently receiving treatment to consider discontinuation or switching to alternative therapies, while urging continued proper use. The Company is examining the impact on its business performance and will make a separate disclosure if any impact becomes apparent.\n\n### Future Response and Impact\nThe Ministry has already notified medical institutions of this policy and provided the drug consultation center as a contact point for healthcare professionals and patients. In the short term, cautious clinical use is expected to continue, requiring consideration of each patient's condition and alternative treatments. The impact on business performance is undetermined, and the Company plans to make additional disclosures depending on future developments.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#PharmaceuticalCompanyIRUpdate, #PharmaceuticalCouncilResponse, #SafetyInformation","jir_key_figures":"Drug consultation center phone number: 0120-007-622\nService hours: 9:00\u201317:40\nPolicy to refrain from initiating treatment for new patients; consideration of discontinuation or switching to alternative treatments for patients currently receiving treatment","jir_meta_title":"Kissei Pharmaceutical Co., Ltd. \u2014 Tabneos Council Results and Response Policy | October 2026","jir_meta_description":"Kissei Pharmaceutical Co., Ltd. announced the report and deliberation results from the Pharmaceutical Affairs and Food Sanitation Council regarding Tabneos and the future dosing policy: refrain from initiating new treatments and consider alternative treatments for current patients. Business impact is undetermined and will be disclosed as appropriate.","jir_og_title":"Kissei Pharmaceutical Co., Ltd. \u2014 Tabneos Council Results and Response Policy | October 2026","jir_og_description":"Announcement of the council results for Tabneos and the response policy, including refraining from initiating treatment and considering alternative therapies. Business impact remains undetermined.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-133271","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n